Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186136 | 0.82 | SLC6A4 (0.71) | SLC6A4NOS2GPR119CYP3A4AAK1 | |
| SCHEMBL2529368 | 0.71 | SLC6A4 (0.54) | SLC6A4NOS2GPR119CYP3A4AAK1 | |
| SCHEMBL6050234 | 0.70 | NOS2 (0.54) | SLC6A4NOS2GPR119SCN9AAR | |
| SCHEMBL25413049 | 0.70 | NOS2 (0.54) | SLC6A4NOS2GPR119SCN9AAR | |
| SCHEMBL6050374 | 0.70 | NOS2 (0.54) | SLC6A4NOS2GPR119SCN9AAR | |
| SCHEMBL2530684 | 0.69 | SLC6A4 (0.54) | SLC6A4NOS2GPR119CYP3A4AAK1 | |
| SCHEMBL2526163 | 0.69 | SLC6A4 (0.52) | SLC6A4NOS2GPR119CYP3A4AAK1 | |
| SCHEMBL2532120 | 0.69 | CNR1 (0.46) | SLC6A4NOS2GPR119KDM4EMEN1 | |
| SCHEMBL6898375 | 0.69 | NOS2 (0.50) | SLC6A4NOS2CYP3A4KDM4EMEN1 | |
| SCHEMBL6050411 | 0.69 | NOS2 (0.50) | SLC6A4NOS2CYP3A4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | claimed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | SLC6A4 1815/4885NOS2 6/4885GPR119 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.